INHIBITORS OF ANGIOGENIC FACTORS

A recombinant human Fc fusion protein comprises an Ig-like domain of a first human VEGF receptor, another different Ig-like domain of a second human VEGF receptor, at least yet another Ig-like domain of a third human VEGF receptor, and the Fc portion of the human IgG1. The fusion protein is useful i...

Full description

Saved in:
Bibliographic Details
Main Authors HU, John Zhenze, SEMBA, Charles, SHEN, Wei Yong, XIA, Zhen Qin, ZHANG, Jinzhong
Format Patent
LanguageEnglish
French
German
Published 06.09.2023
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
ENZYMOLOGY
FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:A recombinant human Fc fusion protein comprises an Ig-like domain of a first human VEGF receptor, another different Ig-like domain of a second human VEGF receptor, at least yet another Ig-like domain of a third human VEGF receptor, and the Fc portion of the human IgG1. The fusion protein is useful in treating or controlling an ocular disease, condition, or disorder that has etiology in aberrant angiogenesis.
Bibliography:Application Number: EP20210885167